

Time	Wednesday, February 15th						
	1F 102 (200)	2F, 201 ABC (400)	2F, 201DEF (400)	3F North Lounge (90)	3F South Lounge (90)	4F Joy Lounge (90)	4F Elegance Lounge (90)
08:00-08:20							
08:20-10:00	Asia Hepatitis Strategy Summit (08:30-10:00)	Post-Graduate Program (HBV)	Young Investigators Workshop APASL-AASLD (08:30-12:10)				
10:00-10:20	Break						
10:20-12:00	Asia Hepatitis Strategy Summit (10:30-12:00)	Post-Graduate Program (MAFLD)					
12:00-13:00				Break			
13:00-14:00	Break			Young Investigators Workshop APASL-AASLD	Young Investigators Workshop APASL-AASLD	Young Investigators Workshop APASL-AASLD	Young Investigators Workshop APASL-AASLD
14:00-15:40	2023 APASL HCV Elimination Policy Forum (13:30-16:00)	Post-Graduate Program (ACLF)	Break	Young Investigators Workshop APASL-AASLD (13:00-16:00) (Viral Hepatitis)	Young Investigators Workshop APASL-AASLD (13:00-16:00) (Cirrhosis Other)	Young Investigators Workshop APASL-AASLD (13:00-16:00) (Fatty Liver Research)	Young Investigators Workshop APASL-AASLD (13:00-16:00) (HCC)
15:40-16:20	Break						
16:20-18:00	2023 APASL HCV Elimination Policy Forum (16:10-17:30)	Post-Graduate Program (HCC)	Young Investigators Workshop APASL-AASLD (16:00-16:50)				
18:30-20:00	Welcome Reception						

Time	Friday, February 17th						
	1F 102 (200)	2F, 201 ABC (400)	2F, 201DEF (400)	3F Plenary Hall (1200)	3F North Lounge (90)	3F South Lounge (90)	4F, VIP Room (250)
08:00-09:00	Meet the expert 1	Meet the expert 2			Meet the expert 3	AARC	Meet the expert 4
	Surveillance of HCC in Patients With HCV after SVR: Who and How?	Checkpoint Inhibitor-induced Immune-mediated Hepatitis			How Should We Manage NASH Patients with Cardiometabolic	Session 1: Optimizing the survival of a patient with ACLF (08:00-09:20)	Beta Blockers in Patients with Cirrhosis and Portal Hypertension: When and How?
09:00-09:30				Plenary Lecture 1 Scott L. Friedman		AARC	
09:30-10:00				Plenary Lecture 2 Chien-Jen Chen		Session 2: Optimizing the transplant free survival (09:25-10:55)	
10:00-10:20	Break / Poster & Exhibition						
10:20-12:00	APASL Symposium 13	APASL Symposium 14	APASL Symposium 15	State-of-the-Art Lecture 7 Vijay H. Shah	Free Paper 7	AARC	APASL Symposium 16
	Liver Diseases in Pregnancy and Children	HCV: Strategy to Eliminate HCV Infection	HCC/CC: Epidemiology, Natural History, Diagnosis, and Staging	State-of-the-Art Lecture 8 Naoko Ohtani State-of-the-Art Lecture 9 Jordi Gracia-Sancho	other infection in liver and MAFLD (basic) 1. Chun-Ying Wu 2. Vincent Wai-Sun Wong	Session 3: Perioperative care of ACLF (11:00-12:30)	Viral Hepatitis Other Than HBV and HCV
12:00-13:30		Satellite Symposium 6 Gilead	Satellite Symposium 7		Satellite Symposium 8 GSK		Satellite Symposium 9 Grifols
13:40-15:20	APASL Symposium 17	APASL Symposium 18	APASL Symposium 19	State-of-the-Art Lecture 10 Zhigang Tian	Free Paper 8	AARC	APASL Symposium 20
	Nutrition and Sarcopenia in Liver Diseases	HCV: Basic Research: Virology and Immunology	HCC/CC: Surgery and Locoregional Therapy	State-of-the-Art Lecture 11. Ann-Lii Cheng State-of-the-Art Lecture 12 Yen-Hsuan Ni	HBV (clinical) 1. Heiner Wedemeyer 2. Tai-Tsung Tseng	Session 4: Post-LT management of ACLF (13:30-14:45) Session 5: Clinical case Scenarios of LT in ACLF (14:50-16:20)	Alcohol Related Liver Disease (ALD) and Drug Induced Liver Injury (DILI)
15:20-15:50	Break / Poster & Exhibition						
15:50-17:30	APASL Symposium 21	APASL Symposium 22	APASL Symposium 23	Joint Symposium 1	Free Paper 9	AARC	APASL Symposium 24
	Multi-Omics and Liver	HCV: Natural History and Current Therapy (Including Special Populations)	HCC/CC: Systemic Therapy Including Early Phase Data for Novel Treatments in Cholangiocarcinoma (15:50-17:05)	EASL-APASL	cirrhosis and ACLF 1. Yasuko Iwakiri 2. Moon-Young Kim	Session 6: Consensus statement of LDLT in ACLF (16:30-17:00) Future Vision of AARC (17:00-17:20)	Special Issues in Asia-Pacific Region (15:50-17:55)
17:30-18:00	Break / Poster & Exhibition						
18:30-21:00	Gala Dinner						

Time	Saturday, February 18th						
	1F 102 (200)	2F, 201 ABC (400)	2F, 201DEF (400)	3F Plenary Hall (1200)	3F North Lounge (90)	3F South Lounge (90)	4F, VIP Room (250)
09:00-09:30				Plenary Lecture 3 Yun-Fan Liaw			
09:30-10:00				Plenary Lecture 4 Shiv Sarin			
10:00-10:20	Break / Poster & Exhibition						
10:20-12:00	APASL Symposium 25	APASL Symposium 26	APASL Symposium 27	Joint Symposium 2	Free Paper 10	Free Paper 11	APASL Symposium 28
	Portal Hypertension and Liver Cirrhosis: Basic Research	HCC/CC: Basic Science and Biomarkers	Application of Artificial Intelligence (AI) and Big Data in Hepatology (I)	AASLD-APASL	MAFLD (basic) 1. Ming-Ling Chang 2. Hung-Wei Wang	HBV (basic) 1. Jaw-Ching Wu 2. Chun-Yen Lin	HBV Reactivation
12:00-13:30	Satellite Symposium 10 Abbvie	Satellite Symposium 11 Eisai	Satellite Symposium 12 Roche		Satellite Symposium 13 Bayer	Satellite Symposium 14	Satellite Symposium 15 Gilead
13:40-15:20	APASL Symposium 29	APASL Symposium 30	APASL Symposium 31	State-of-the-Art Lecture 13 Jia-Hong Kao	Free Paper 12	Free Paper 13	APASL Symposium 32
	Portal Hypertension and Liver Cirrhosis: Natural History, Complications, and Potential Novel Treatments	HCC/CC: Systemic Therapy Including Early Phase Data for Novel Treatments in HCC (13:40-15:45)	Application of Artificial Intelligence (AI) and Big Data in Hepatology (II) (13:40-15:45)	State-of-the-Art Lecture 14 Won-Il Jeong State-of-the-Art Lecture 15 Ji-Dong Jia	MAFLD (clinical) 1. Wan-Long Chuang 2. Saeed Hamid	HBV (clinical) 1. Tsung-Hui Hu 2. I-Cheng Lee	COVID-19 and the Liver
15:20-15:50	Break / Poster & Exhibition			Break / Poster & Exhibition			
15:50-17:30	APASL Symposium 33			Grand Round	Free Paper 14	Free Paper 15	APASL Symposium 34
	HCV: Extrahepatic Manifestation of HCV			Acute-on-chronic Liver Failure	MAFLD (clinical) 1. Ching-Sheng Hsu 2. Ming-Lun Yeh	Miscellaneous 1. Huey-Ling Chen 2. Saeed Hamid	Liver Transplantation
17:40-19:00		Satellite Symposium 16 Gilead	Satellite Symposium 17 Eisai		Satellite Symposium 18 AstraZeneca	Satellite Symposium 19 BMS	Satellite Symposium 20

Time	Sunday, February 19th	
08:00-09:00	2F, 201 ABC (400)	2F, 201DEF (400)
09:00-10:30	YIA Award	Coalition to Eradicate Viral Hepatitis in Asia Pacific (CEVHAP) symposium
10:30-10:50	Break	
10:50-12:30	APASL 2023 Scientific Debrief: Hepatitis, Cirrhosis, Liver Cancer, NASH	Coalition to Eradicate Viral Hepatitis in Asia Pacific (CEVHAP) symposium
12:30-13:00	Closing Ceremony	

APASL 2023 Daily Program

Wednesday, February 15th

Registration

1F lobby

08:00

Asia Hepatitis Strategy Summit

Room 102

08:30-10:00

Time	No.	Name	City	Topic
08:30-08:40	Moderator	Chien-Jen Chen	Taipei	WHO Hepatitis Elimination Goal and Taiwan's Achievement
08:40-08:55		John Ward	Georgia	WHO'S Goal
08:55-09:10		Jasmine Pwu	Taipei	Toward Hepatitis C Elimination by 2025 - Taiwan Policy and Strategies
09:10-09:20	Moderator	Jia-Horng Kao	Taipei	HCV Progress to Eliminate & Best Practice
09:20-09:30		Ming-Lung Yu	Kaohsiung	HCV Progress to Eliminate & Best Practice: Taiwan
09:30-09:40		Tetsuo Takehara	Osaka	HCV Progress to Eliminate & Best Practice: Japan
09:40-09:50		Jacob George	Sydney	HCV Progress to Eliminate & Best Practice: Australia
09:50-10:00	Panel Discussion: What's the Next Step Towards Elimination			
	Moderator	Jia-Horng Kao		
	Panelists	Ming-Lung Yu		
		Tetsuo Takehara		
		Jacob George		

Post-Graduate Program (HBV)

Room 201ABC

08:20-10:00

Moderator	Cheng-Yuan Peng (Taichung)			
Time	No.	Name	City	Topic
08:20-08:45		Young-Suk Lim	Seoul	Treatment Indication in Non-Cirrhotic Patients
08:45-09:10		Wen-Juei Jeng	Taoyuan	Finite Therapy in HBeAg-Negative Patients
09:10-09:35		Sang Hoon Ahn	Seoul	Evolution of Liver Fibrosis in Patients Under Long-Term NA Therapy

09:35-10:00		Hwai-I Yang	Taipei	Prediction Model of HCC in NA-Treated Patients
Young Investigators Workshop APASL-AASLD				
				Room 201DEF
08:30-12:10				
Moderator	TBC			
Time	No.	Name	City	Topic
08:30-08:35		Ray Kim	San Francisco	Introduction
08:30-08:35		Tung-Hung Su	Taipei	Introduction
08:35-08:55		Norah Terrault	San Francisco	Hot Topics in Hepatobiliary Malignancies in Asia and US
08:55-09:20		Fasiha Kanwal	Houston	Measuring Incidence and Prevalence of Cancer in the Population
09:20-09:45		Mei-Hsuan Lee	Taipei	Cohort Studies to Investigate Causation
09:45-10:10		Ray Kim	San Francisco	Case Control Studies in Cancer
10:30-10:55		Xin Wei Wang	Bethesda	Development and Validation of a Cancer Biomarker
10:55-11:20		Yao-Chun Hsu	Kaohsiung	Systematic Review and Meta-Analysis
11:20-11:45		Yi-Hsiang Huang	Taipei	Real World Studies of HCC
11:45-12:10		Terry Cheuk-Fung Yip	Hong Kong	Statistics for Non-Statisticians
Post-Graduate Program (MAFLD)				
				Room 201ABC
10:20-12:00				
Moderator	Jee-Fu Huang (Kaohsiung)			
Time	No.	Name	City	Topic
10:20-10:45		Jacob George	Sydney	Definition of MAFLD
10:45-11:10		Grace Lai-Hung Wong	Hong Kong	Assessment of Liver Fibrosis in MAFLD
11:10-11:35		Pierre Nahon	Paris	HCC in MAFLD
11:35-12:00		Nicholas W S Chew	Singapore	MAFLD and Cardiovascular Diseases
Asia Hepatitis Strategy Summit				
				Room 102
10:30-12:00				
Moderator	Jia-Horng Kao (Taipei)			
Time	No.	Name	City	Topic

10:30-11:00		Douglas Dieterich	New York	HBV Strategy to Achieve WHO's HBV Goal: Simplification of HBV Treatment and the Benefits of Earlier Treatment
11:00-12:00	Moderator	Jia-Horng Kao	Taipei	HBV Strategy in Asia
11:00-11:13		Chun-Jen Liu	Taipei	HBV Strategy in Asia: Taiwan
11:13-11:26		Young-Suk Lim	Seoul	HBV Strategy in Asia: Korea
11:26-11:39		Grace Lai-Hung Wong	Hong Kong	HBV Strategy in Asia: Hong Kong
11:40-12:00		Panel Discussion		

Young Investigators Workshop APASL-AASLD

				Room 201DEF
13:00-14:00				
Moderator	TBC			
Time	No.	Name	City	Topic
13:00-14:00		Homie Razavi	Lafayette	How I Did My Study?
13:00-14:00		Jasmohan S. Bajaj	Richmond	How I Did My Study?
13:00-14:00		Gyongyi Szabo	Boston	How I Did My Study?
13:00-14:00		Ray Kim	San Francisco	How I Did My Study?
13:00-14:00		Chun-Jen Liu	Taipei	How I Did My Study?
13:00-14:00		Grace Lai-Hung Wong	Hong Kong	How I Did My Study?
13:00-14:00		Young-Suk Lim	Seoul	How I Did My Study?
13:00-14:00		Shiv Kumar Sarin	New Delhi	How I Did My Study?

Forum: How Can a National Policy on HCV Elimination Help Achieve WHO Goals?

				Room 102
13:30-16:00				
Time	No.	Name	City	Topic
13:30-13:40	Moderator	Chien-Jen Chen	Taipei	Opening Address
13:40-14:20		Chien-Jen Chen	Taipei	Section (I) Global & Regional Perspectives~ PATIENTS AS NORTH STAR
13:40-14:00		Philippa Easterbrook	Geneva	Guidelines on Simplified Service Delivery & the WHO Elimination Guidance and Criteria for Validation of Elimination
14:00-14:20		John Ward	Georgia	HCV Elimination Progress Among Asia Countries ~ Achievements& Opportunities

14:20-15:20	Moderator	Naoya Kato	Tokyo	Section (II) Elimination Policy in General Population~ HEP C CAN'T WAIT
14:20-14:40		Christoph Sarrazin	Wiesbaden	National Screening & Treatment
14:40-15:00		Norifumi Kawada	Osaka	Elimination Network in Care Cascade
15:00-15:10		Jae Young Jang	Seoul	Feasibility of National HCV Screening
15:10-15:20		Jin Gwack		National HCV Screening Strategies
15:20-16:00	Panel Discussion			
	Moderator	SiHyun Bae	Seoul	
	Panelists	Christoph Sarrazin	Wiesbaden	
		Norifumi Kawada	Osaka	
		Jae Young Jang	Seoul	
		Jin Gwack		
		Jasmine Pwu	Taipei	
		Junko Tanaka	Hiroshima	
		Jeemin Park		

Forum: How Can a National Policy on HCV Elimination Help Achieve WHO Goals?

Room 102

16:10-17:30

Time	No.	Name	City	Topic
16:10-17:30	Moderator	Rahul Kumar	Singapore	Section (III) Elimination Policy in Special Population~ NO PATIENT LEFT BEHIND
16:10-16:25		Ming-Lung Yu	Kaohsiung	Prisoners Test & Treatment
16:25-16:40		Grace Lai-Hung Wong	Hong Kong	PWID Test & Treatment
16:40-17:05		Ming-Lung Yu	Kaohsiung	Panel Discussion
16:40-17:05		Grace Lai-Hung Wong	Hong Kong	Panel Discussion

16:40-17:05	Owen Tsang	Singapore	Panel Discussion
-------------	------------	-----------	------------------

16:40-17:05	Yen-Po Yeh	Changhua	Panel Discussion
-------------	------------	----------	------------------

16:40-17:05	Ka-Hing Wong	Hong Kong	Panel Discussion
-------------	--------------	-----------	------------------

17:05-17:20	John Ward	Georgia	What Dose Success Look Like~ Call to Action
-------------	-----------	---------	---

17:20-17:30	Ming-Lung Yu	Kaohsiung	Feedback & Closing Remarks
-------------	--------------	-----------	----------------------------

Post-Graduate Program (ACLF)

Room 201ABC

14:00-15:40

Moderator Chun-Yen Lin (Taoyuan)

Time	No.	Name	City	Topic
14:00-14:25		Ashok Choudhury	New Delhi	Definition of ACLF
14:25-14:50		Richard Moreau	Paris	Acute Kidney Injury in ACLF
14:50-15:15		Jun Li	Zhejiang	Prognostic Models for ACLF
15:15-15:40		Viniyendra Pamecha	New Delhi	Liver Transplantation in ACLF

Young Investigators Workshop APASL-AASLD: Poster Session-Viral Hepatitis

North Lounge

13:00-16:00

Moderator Norah Terrault (San Francisco)/Fasiha Kanwal (Houston)/
Tung Hung Su (Taipei)/Rong-Nan Chien (Taoyuan)

Young Investigators Workshop APASL-AASLD: Poster Session-Cirrhosis Other

South Lounge

13:00-16:00

Moderator Ying-Ying Yang (Taipei)/Seung Up Kim (Seoul)/
Hui-Chun Huang (Taipei)/Kuei-Chuan Lee (Taipei)

Young Investigators Workshop APASL-AASLD: Poster Session-Fatty Liver Research

Joy Lounge

13:00-16:00

Moderator Gyongyi Szabo (Boston)/ Pin-Nan Cheng (Tainan)
Vincent Wai-Sun Wong (Hong Kong)/Jee-Fu Huang (Kaohsiung)

Young Investigators Workshop APASL-AASLD: Poster Session-HCC

Elegance Lounge

13:00-16:00

Moderator Mazen Nouredin (Los Angeles)/Neil Mehta (Cleveland)/
Hung-Chih Yang (Taipei)/Chiun Hsu (Taipei)

Young Investigators Workshop APASL-AASLD

Room 201DEF

16:00-16:50

Time	No.	Name	City	Topic
16:00-16:20		David E. Cohen	Boston	Editor's Perspective-What Makes a Great Paper
16:20-16:40		Sunny H. Wong	Singapore	Effective Presentation of Data: Tables and Figure
16:40-16:50		Ray Kim	San Francisco	Closing and Awarding

16:40-16:50	Tung-Hung Su	Taipei	Closing and Awarding
-------------	--------------	--------	----------------------

Post-Graduate Program (HCC)

Room 201ABC

16:20-18:00

Moderator Yi-Hsiang Huang (Taipei)

Time	No.	Name	City	Topic
16:20-16:45		Fasiha Kanwal	Houston	Surveillance of HCC
16:45-17:10		Masatoshi Kudo	Osaka	Systemic Therapy in Intermediate-Stage HCC
17:10-17:35		Chiun Hsu	Taipei	Immunotherapy in Advanced HCC
17:35-18:00		Chung-Feng Huang	Kaohsiung	Antiviral Therapy in Patients with Intermediate-Stage and Advanced HCC

Welcome Reception

18:30-20:00

Thursday, February 16th

Registration

Room 102

08:30

APASL Symposium 1-Writing and Publishing Good Paper

Room 102

09:00-10:40

Moderator Ming-Shiang Wu (Taipei)/Jaw Ching Wu (Taipei)/Chun-Jen Liu (Taipei)

Time	No.	Name	City	Topic
09:00-09:25		Emad M El-Omar	Sydney	How the Editors Judge the Significance, Novelty, and Quality of Research Articles Submitted to Top Journals?
09:25-09:50		Francis KL Chan	Hong Kong	How to Get Your Papers Published in Top Journals in the Field of General and Internal Medicine?
09:50-10:15		Robert Brierley	London	How to Publish Your Paper in Lancet Journals
10:15-10:40		Huey-Ling Chen	Taipei	How to Get Your Clinical Research Papers Published in Top Journals in the Field of Gastroenterology and Hepatology?

APASL Symposium 2-MAFLD: Basic Research

Room 201ABC

09:00-10:40

Moderator Kuei-Chuan Lee (Taipei)/ Gyongyi Szabo (Boston)

Time	No.	Name	City	Topic
09:00-09:25		Luca Valenti	Milan	Epigenomics and Genomics for MAFLD Phenotypes and Outcomes
09:25-09:50		Ming-Ling Chang	Taoyuan	Crucial Nutrients and Biomolecules for MAFLD Outcomes: The Good, the Bad, and the Ugly
09:50-10:15		Dong Joon Kim	Chuncheon	Microbiota and MAFLD: The Gut-Liver Axis
10:15-10:40		Ying-Ying Yang	Taipei	Crucial Pathways for MAFLD Phenotypes and Outcomes

APASL Symposium 3-HBV: Prevention, Natural History, Current Therapy and Indication

Room 201DEF

09:00-10:40

Moderator Rong-Nan Chien (Taoyuan)/Cheng-Yuan Peng (Taichung)

Time	No.	Name	City	Topic
09:00-09:25		Huey-Ling Chen	Taipei	Universal HBV Vaccination Program in Asian Pacific Region

09:25-09:50	Seng Gee Lim	Singapore	HBcrAg - Not as Good as It Seems
09:50-10:15	Wen-Juei Jeng	Taoyuan	Stop-and-Watch Strategy in HBeAg-negative Off-Nuc Therapy
10:15-10:40	Pietro Lampertico	Milan	Stop-to-Cure Strategy in HBeAg-negative Off-Nuc Therapy

State-of-the-Art Lecture 1

				Plenary Hall
09:00-09:30				
Moderator	Masao Omata (Tokyo)			
Time	No.	Name	City	Topic
09:00-09:30		Pei-Jer Chen	Taipei	Liver-Targeting Therapies for Systemic Diseases

State-of-the-Art Lecture 2

				Plenary Hall
09:35-10:05				
Moderator	Wan-Long Chuang (Kaohsiung)			
Time	No.	Name	City	Topic
09:35-10:05		David E. Cohen	Boston	Energy Expenditure as a Therapeutic Strategy in Non-Alcoholic Fatty Liver Disease

State-of-the-Art Lecture 3

				Plenary Hall
10:10-10:40				
Moderator	Jose Sollano (Manila)			
Time	No.	Name	City	Topic
10:10-10:40		Jacob George	Sydney	Applications of Big Data in MAFLD Studies

Free Paper 1: Cirrhosis

				North Lounge
09:00-10:40				
Moderator	Gin-Ho Lo / Hung-Wei Wang			

Free Paper 2: Liver Cancer

				South Lounge
09:00-10:40				
Moderator	Osamu Yokosuka / Shi-Ming Lin			

APASL Symposium 4-Liver Injury and Regeneration

				VIP Room
--	--	--	--	----------

09:00-10:40				
Moderator	Shiou-Hwei Yeh (Taipei)/Sen-Yung Hsieh (Taoyuan)			
Time	No.	Name	City	Topic
09:00-09:25		Stuart Forbes	Edinburgh	Liver Regeneration and Inflammation: From Fundamental Science to Clinical Applications
09:25-09:50		Hao Zhu	Dallas	Linkage of Injury and Regeneration with Carcinogenesis in the Liver
09:50-10:15		Naoki Tanimizu	Tokyo	Liver Regeneration in Response to Acute and Chronic Liver Injury
10:15-10:40		Sen-Yung Hsieh	Taoyuan	Gut Microbiota in Acute Liver Injury and Regeneration

Break/Poster & Exhibition				
10:40-11:00				

Opening Ceremony				
Plenary Hall				
11:00-11:30				

Time	No.	Name	City	Topic
11:00-11:05		Opening Performance		
11:05-11:08		Han-Chieh Lin	Taipei	
11:08-11:11		Shiv Kumar Sarin	New Delhi	
11:11-11:14		Masao Omata	Tokyo	
11:14-11:17		Ming-Shiang Wu	Taipei	
11:17-11:20		Chun-Jen Liu	Taipei	
11:20-11:30		Group Photo		

Presidential Lecture				
Plenary Hall				
11:30-12:00				
Moderator	Shou-Dong Lee (Taipei)			
Time	No.	Name	City	Topic
11:30-12:00		Han-Chieh Lin	Taipei	Revisiting the Role of Non-Selective β-blockers in Patients with Cirrhosis and Portal Hypertension

Satellite Symposium 1				
Room 201 ABC				
12:00-13:30				

Satellite Symposium 2

Room 201DEF

12:00-13:30

Satellite Symposium 3

North Lounge

12:00-13:30

Satellite Symposium 4

South Lounge

12:00-13:30

Satellite Symposium 5

VIP Room

12:00-13:30

APASL Symposium 5-Presentation Skills

Room 102

13:40-15:20

Moderator Huey-Ling Chen (Taipei)

Time	No.	Name	City	Topic
13:40-13:55		Yao-Chun Hsu	Kaohsiung	Scientific Presentation: A Critical Skill for Our Career Path
13:55-14:10		Huey-Ling Chen	Taipei	Know thy Audience (Scientific and Non-Scientific)
14:10-14:30	Panel Discussion I			
14:30-14:45		Chiun Hsu	Taipei	In the Battleground: Presentation/Communication at Advisory Meetings
14:45-15:00		Chun-Ying Wu	Taipei	TEAM: Together Everybody Achieves More
15:00-15:20	Panel Discussion II			

APASL Symposium 6-MAFLD: Diagnosis, Natural History, Biomarkers, and Cancer

Room 201ABC

13:40-15:20

Moderator Kuei-Chuan Lee (Taipei)/Hwai-i Yang (Taipei)

Time	No.	Name	City	Topic
13:40-14:05		Rohit Loomba	San Diego	Natural History of MAFLD

14:05-14:30	Grace Lai-Hung Wong	Hong Kong	Approaches for the Prediction of MAFLD and Fibrosis
14:30-14:55	Shiu-Feng Huang	Miaoli	HCC and Fatty Liver: A Study in Taiwan
14:55-15:20	Yoshio Sumida	Nagakute	MAFLD in Japan and the Risk Factor for HCC

APASL Symposium 7-HBV: Virology and Immunology

Room 201DEF

13:40-15:20

Moderator Seng Gee Lim (Singapore)/Pei-Jer Chen (Taipei)

Time	No.	Name	City	Topic
13:40-14:05		Chun-Yen Lin	Taoyuan	HBV-Induced Immune Response in the Development of HCC
14:05-14:30		Masanori Isogawa	Nagoya	Mechanisms of HBV Immune Evasion
14:30-14:55		Haitao Guo	Indianapolis	Molecular Mechanism for HBV cccDNA Biosynthesis
14:55-15:20		Shiou-Hwei Yeh	Taipei	New Insights of HBV Morphogenesis

Award Session

Plenary Hall

13:40-15:00

Time

13:40-14:00	Okuda-Omata Distinguished Award
14:00-14:20	Powell-Sarin Achievement Award
14:20-14:40	Lesmana-Sollano Great Mentor Award
14:40-15:00	Rising Star Award

Free Paper 3: HBV (Clinical) and HCV

North Lounge

13:40-15:20

Moderator Sang Hoon Ahn / Chen-Hua Liu

Free Paper 4: Liver Cancer

South Lounge

13:40-15:20

Moderator Stephen Lam Chan / Wei-Yu Kao

APASL Symposium 8-Liver Fibrosis and Treatment

VIP Room				
13:40-14:55				
Moderator	A. Kadir Dokmeci (Ankara)/Sen-Yung Hsieh (Taoyuan)			
Time	No.	Name	City	Topic
13:40-14:05		Sophie Lotersztajn	Paris	Targeting Cell-Intrinsic Metabolism for Antifibrotic Therapy
14:05-14:30		Matthew M. Yeh	Seattle	Pathology as a Mirror of Liver Disease Progression in Hepatic Fibrosis
14:30-14:55		Kuei-Chuan Lee	Taipei	Liver Fibrosis and Cirrhosis: From Bench to Bedside
APASL Symposium 9-Autoimmune Liver Disease				
Room 102				
15:50-17:30				
Moderator	Ming-Ling Chang (Taoyuan)/Chien-Wei Su (Taipei)			
Time	No.	Name	City	Topic
15:50-16:15		Ming-Ling Chang	Taoyuan	Global Trends of Rates and Outcomes of AILD: A 2023 Update
16:15-16:40		Chang-Youh Tsai	Taipei	Current Therapy of Various AILD: A Viewpoint from the East
16:40-17:05		Ulrich Beuers	Amsterdam	Current Therapy of Various AILD: A Viewpoint from the West
17:05-17:30		Atsushi Tanaka	Tokyo	Interference Between AILD and Other Major Liver Diseases
APASL Symposium 10-MAFLD: Therapy (Lifestyle Modification, and Drugs)				
Room 201ABC				
15:50-17:30				
Moderator	George Lau (Hong Kong)/Pin-Nan Cheng (Tainan)			
Time	No.	Name	City	Topic
15:50-16:15		Jee-Fu Huang	Kaohsiung	Patient Management: Risk Stratification
16:15-16:40		Chun-Jen Liu	Taipei	Patient Management: Lifestyle Modification
16:40-17:05		Vincent Wai-Sun Wong	Hong Kong	Pharmacotherapy: Past and Current

17:05-17:30		Rohit Loomba	San Diego	Pharmacotherapy: Preclinical and Early Phases
-------------	--	--------------	-----------	---

APASL Symposium 11-HBV: Novel Therapeutic Approaches				
				Room 201DEF
15:50-17:05				
Moderator	Tsung-Hui Hu (Kaohsiung)			
Time	No.	Name	City	Topic
15:50-16:15		Hung-Chih Yang	Taipei	HBV Life Cycle and Main Targets of Direct and Indirect Viral Therapies
16:15-16:40		Man Fung Yuen	Hong Kong	Novel Direct Antiviral Agents Against HBV
16:40-17:05		Antonio Bertoletti	Singapore	Novel Immune-Modulating Agents Against HBV and the Challenge to Select Responsive Patients

State-of-the-Art Lecture 4				
				Plenary Hall
15:50-16:20				
Moderator	Shiu-Feng Huang (Miaoli)			
Time	No.	Name	City	Topic
15:50-16:20		Sophie Lotersztajn	Paris	Immunoregulation of Liver Fibrosis: From Pathogenesis to Treatment

State-of-the-Art Lecture 5				
				Plenary Hall
16:25-16:55				
Moderator	Chao-Long Chen (Kaohsiung)			
Time	No.	Name	City	Topic
16:25-16:55		Neil Mehta	Cleveland	Downstaging Outcomes for Hepatocellular Carcinoma Before Liver Transplantation

State-of-the-Art Lecture 6				
				Plenary Hall
17:00-17:30				
Moderator	Ann-Lii Cheng (Taipei)			
Time	No.	Name	City	Topic
17:00-17:30		Masatoshi Kudo	Osaka	Nobel Treatment Strategy in Intermediate-Stage HCC

Free Paper 5: HBV (Clinical)				
				North Lounge
15:50-17:30				
Moderator	Wen-Juei Jeng / Yao-Chun Hsu			

Free Paper 6: Portal Hypertension, Cirrhosis

South Lounge

15:50-17:30

Moderator Osamu Yokosuka / Ming-Hung Tsai

APASL Symposium 12-Microbiota and Liver Disease

VIP Room

15:50-17:30

Moderator Kuei-Chuan Lee (Taipei)/An-Ming Yang (New Taipei City)

Time	No.	Name	City	Topic
15:50-16:15		Ting-Chin David Shen	Pennsylvania	Deciphering Gut Microbiome Signatures for Acute on Chronic Hepatitis
16:15-16:40		Sunny H. Wong	Singapore	Harnessing Microbiome for Immune Modulation in Liver Cancer
16:40-17:05		An-Ming Yang	New Taipei City	Intestinal Fungi Contribution to Development of Metabolic Dysfunction-Associated Fatty Liver Disease
17:05-17:30		Ming-Shiang Wu	Taipei	The Impact of Bariatric Surgery on Gut Microbiota and Non-Alcoholic Fatty Liver Disease

Faculty Dinner

18:30-20:30

Friday, February 17th

Registration

1F lobby

07:30

Meet the Expert 1

Room 102

08:00-09:00

Time	No.	Name	City	Topic
08:00-9:00		Ming-Lung Yu	Kaohsiung	Surveillance of HCC in Patients with HCV after SVR: Who and How?
08:00-9:00		Pierre Nahon	Paris	Surveillance of HCC in Patients with HCV after SVR: Who and How?

Meet the expert 2

Room 201ABC

08:00-09:00

Time	No.	Name	City	Topic
08:00-09:00		Stephen Lam Chan	Hong Kong	Checkpoint Inhibitor-Induced Immune-Mediated Hepatitis
08:00-09:00		Chih-Hung Hsu	Taipei	Checkpoint Inhibitor-Induced Immune-Mediated Hepatitis

Meet the Expert 3

North Lounge

08:00-09:00

Time	No.	Name	City	Topic
08:00-09:00		Vincent Wai-Sun Wong	Hong Kong	How Should We Manage Nash Patients with Cardiometabolic Disease?
08:00-09:00		Jee-Fu Huang	Kaohsiung	How Should We Manage Nash Patients with Cardiometabolic Disease?

Meet the Expert 4

VIP Room

08:00-09:00

Time	No.	Name	City	Topic
------	-----	------	------	-------

08:00-09:00	Hui-Chun Huang	Taipei	Beta Blockers in Patients with Cirrhosis and Portal Hypertension: When and How?
08:00-09:00	Richard Moreau	Paris	Beta Blockers in Patients with Cirrhosis and Portal Hypertension: When and How?

AARC Session 1: Optimizing the Survival of a Patient with ACLF

South Lounge

08:00-09:20

Time	No.	Name	City	Topic
08:00-08:10		Han-Chieh Lin		Welcome and Concept of Collaborative Studies in APASL
08:10-08:20	Moderator	Masao Omata	Tokyo	ACLF in 2023- Where Are We 15 Years Later
08:10-08:20		Shiv Kumar Sarin		ACLF in 2023- Where Are We 15 Years Later
08:20-08:35	Moderator	Richard Moreau		Managing Acute Precipitant of ACLF
08:20-08:35		Grace Lai-Hung Wong		Managing Acute Precipitant of ACLF
08:35-08:50	Moderator	Hasmik Ghazinyan		Managing Steroid Non-Response Without LT in Alcohol Associated ACLF
08:35-08:50		Vijay H. Shah		Managing Steroid Non-Response Without LT in Alcohol Associated ACLF
08:50-09:05	Moderator	Kadir Dockmechi		Reversibility of ACLF
08:50-09:05		Ashok Choudhury		Reversibility of ACLF
09:05-09:20	Moderator	Dong Joon Kim		ACLF: Is Primary Prevention Possible
09:05-09:20		Naoko Ohtani		ACLF: Is Primary Prevention Possible

Plenary Lecture 1

Plenary Hall

09:00-09:30

Moderator Pei-Jer Chen (Taipei)

Time	No.	Name	City	Topic
09:00-09:30		Scott L. Friedman	New York	Evolving Challenges in Hepatic Fibrosis

AARC Session 2: Optimizing the Transplant Free Survival

South Lounge

09:25-10:55

Time	No.	Name	City	Topic
09:25-09:40	Moderator	Gamal Shiha		Infections and Prophylaxis in ACLF and Their Implications on Transplantation
09:25-09:40		Qing Ning		Infections and Prophylaxis in ACLF and Their Implications on Transplantation
09:40-09:55	Moderator	Jennifer C. Lai		Defining Futility in ACLF/Palliation in ACLF
09:40-09:55		Jin Hua Hua		Defining Futility in ACLF/Palliation in ACLF
09:55-10:10	Moderator	Manoj Sharma		Organ Support in ACLF
09:55-10:10		Ming-Lung Yu		Organ Support in ACLF
10:10-10:25	Moderator	Young-Suk Lim		Protocolized Nutrition in ACLF: Pre-Peri--Post Operative
10:10-10:25		David E. Cohen		Protocolized Nutrition in ACLF: Pre-Peri--Post Operative
10:25-10:40	Moderator	Mazen Nouredin		Regenerative and Cell Based Therapy in ACLF: What, When and How?
10:25-10:40		Stuart Forbes		Regenerative and Cell Based Therapy in ACLF: What, When and How?
10:40-10:55	Moderator	Chien-Hung Chen		Management of Ascites, Hyponatremia and AKI in ACLF
10:40-10:55		Sombat		Management of Ascites, Hyponatremia and AKI in ACLF

Plenary Lecture 2

Plenary Hall

09:30-10:00

Moderator Shiv Kumar Sarin (New Delhi)

Time	No.	Name	City	Topic
09:30-10:00		Chien-Jen Chen	Taipei	International Collaboration and Paradigm Shift in Hepatology: Precision Health and Innovation

APASL Symposium 13-Liver Diseases in Pregnancy and Children

Room 102

10:20-12:00

Moderator Huey-Ling Chen (Taipei)/Winita Hardikar (Melbourne)

Time	No.	Name	City	Topic
10:20-10:45		Mei-Hwei Chang	Taipei	HBV Control: Starting Before Birth to Life-Long Care

10:45-11:10	Ka Wang Cheung	Hong Kong	Optimal Management of Pregnant Women with HBV Infection and Other Liver Diseases
11:10-11:35	Winita Hardikar	Melbourne	The Changing Landscape of Paediatric PSC
11:35-12:00	Ayano Inui	Kanagawa	Emerging Liver Diseases in Children: Keys to New Diagnosis and Treatment

APASL Symposium 14-HCV: Strategy to Eliminate HCV Infection

Room 201ABC

10:20-12:00

Moderator Sheng-Nan Lu (Kaohsiung)/Ming-Lung Yu (Kaohsiung)

Time	No.	Name	City	Topic
10:20-10:45		Benjamin Cowie	Melbourne	Interim Guidance for Country Validation of Viral Hepatitis Elimination
10:45-11:10		Chien-Jen Chen	Taipei	Taiwan's National Strategies and Actions Toward HCV Elimination Before 2025
11:10-11:35		Homie Razavi	Lafayette	Global Timing of Hepatitis C Virus Elimination in High-Income Countries.
11:35-12:00		Lindsey Hiebert	Boston	Retreatment of Chronic Hepatitis Infection: Real-World Regimens and Outcomes from National Treatment Programs in Three Low-And Middle-Income Countries.

APASL Symposium 15-HCC/CC: Epidemiology, Natural History, Diagnosis, and Staging

Room 201DEF

10:20-12:00

Moderator Po Chin Liang (Taipei)/Shiu-Feng Huang (Miaoli)

Time	No.	Name	City	Topic
10:20-10:45		Yasuni Nakanuma	Kanazawa	Pathologic Diagnosis of HCC/CC
10:45-11:10		Chih-Horng Wu	Taipei	Imaging Subclassification of Intrahepatic Cholangiocarcinoma: A Correlation with Pathological Findings and Clinical Outcome
11:10-11:35		Li-Tzong Chen	Kaohsiung	Precision Medicine (Genetic and Target Agents)
11:35-12:00		Po-Da Chen	Taipei	Long-Term Survival of Combined Hepatocellular Carcinoma-Cholangiocarcinoma: A Nationwide Study

State-of-the-Art Lecture 7

Plenary Hall

10:20-10:50

Moderator Teerha Piratvisuth (Songkhla)

Time	No.	Name	City	Topic
17:00-17:30		Vijay H. Shah	Minnesota	The Digital Transformation of Hepatology

State-of-the-Art Lecture 8

Plenary Hall

10:55-11:25

Moderator Ming-Shiang Wu (Taipei)

Time	No.	Name	City	Topic
10:55-11:25		Naoko Ohtani	Osaka	Gut-Liver Axis-Mediated Mechanism of Liver Cancer

State-of-the-Art Lecture 9

Plenary Hall

11:30-12:00

Moderator Ying-Ying Yang (Taipei)

Time	No.	Name	City	Topic
11:30-12:00		Jordi Gracia-Sancho	Barcelona	Vascular Pathology and Liver Microcirculation in Cirrhotic Portal Hypertension

Free Paper 7: Other Infection in Liver and MAFLD (Basic)

North Lounge

10:20-12:00

Moderator Chun-Ying Wu / Vincent Wai-Sun Wong

APASL Symposium 16-Viral Hepatitis Other Than HBV and HCV

VIP Room

10:20-12:00

Moderator George V. Papatheodoridis (Athens)/Tsung-Hui Hu (Kaohsiung)

Time	No.	Name	City	Topic
10:20-10:45		Chien-Wei Su	Taipei	Epidemiology and Natural History of Hepatitis D
10:45-11:10		Heiner Wedemeyer	Hanover	Novel Treatment of Chronic Hepatitis D
11:10-11:35		Subrat Kumar Panda	New Delhi	Updates in Biology of HEV
11:35-12:00		Chien-Ching Hung	Taipei	HAV Infection in People Living With HIV

AARC Session 3: Perioperative Care of ACLF

South Lounge

11:00-12:30

Time	No.	Name	City	Topic
11:00-11:15	Moderator	Sanjiv Saigal		Severity Scores in Listing and Determining Outcomes of LT
11:00-11:15		Mamta Bhat		Severity Scores in Listing and Determining Outcomes of LT
11:15-11:30	Moderator	Francis KL Chan		Donor Considerations in LDLT for ACLF
11:15-11:30		Viniyendra Pamecha		Donor Considerations in LDLT for ACLF
11:30-11:45	Moderator	Rinaldi Lesmana		Ideal Timing for Liver Transplant in ACLF
11:30-11:45		Jia ji Dong		Ideal Timing for Liver Transplant in ACLF
11:45-12:00	Moderator	J J Chun		Protocolized Nutrition in ACLF: Pre-peri--Post Operative
11:45-12:00		David E. Cohen		Protocolized Nutrition in ACLF: Pre-peri--Post Operative
12:00-12:15	Moderator	Tawaseek Tanwandi		Management of Ascites, Hyponatremia and AKI in ACLF
12:00-12:15		Sombat		Management of Ascites, Hyponatremia and AKI in ACLF
12:15-12:30	Moderator	Sen-Yung Hsieh		Recipient Considerations Including Recent Alcohol Intake
12:15-12:30		M Rela		Recipient Considerations Including Recent Alcohol Intake

Satellite Symposium 6 Gilead

Room 201 ABC

12:00-13:30

Satellite Symposium 7

Room 201 DEF

12:00-13:30

Satellite Symposium 8 GSK

North Lounge

12:00-13:30

Satellite Symposium 9 Grifols

VIP Room

12:00-13:30

AARC Session 4: Post-LT Management of ACLF

South Lounge

13:30-14:45

Time	No.	Name	City	Topic
13:30-13:45	Moderator	Diana Payawal		Surgical Considerations and Post-operative Care in ACLF
13:30-13:45		Korean Colleague/S G Lee		Surgical Considerations and Post-operative Care in ACLF
13:45-14:00	Moderator	Jasmohan S. Bajaj		Immunosuppression in ACLF Following LT: Is It Different?
13:45-14:00		George Lau		Immunosuppression in ACLF Following LT: Is It Different?
14:00-14:15	Moderator	Fasiha Kanwal		Metabolic Complications and Management Following LT
14:00-14:15		Soek-Siam Tan		Metabolic Complications and Management Following LT
14:15-14:30	Moderator	Chieu-Hao Huang		Long Term Outcomes of Patients with ACLF Following LT
14:15-14:30		Geoff McCaughan		Long Term Outcomes of Patients with ACLF Following LT
14:30-14:45	Moderator	Madunil A Niriella		Healthcare Utilization by ACLF Patients-is Survival the Only Benefit?
13:30-14:45		Mark Mutaiah		Healthcare Utilization by ACLF Patients-is Survival the Only Benefit?

Free Paper 8: HBV (Clinical)

North Lounge

13:40-15:20

Moderator Heiner Wedemeyer / Tai-Tsung Tseng

APASL Symposium 17-Nutrition and Sarcopenia in Liver Diseases

Room 102

13:40-15:20

Moderator Jin Mo Yang (Seoul)/Ying-Ying Yang (Taipei)

Time	No.	Name	City	Topic
13:40-14:05		Jennifer C. Lai	San Francisco	Malnutrition, Frailty, and Sarcopenia in Patients with Cirrhosis
14:05-14:30		Seung Up Kim	Seoul	Sarcopenia and Liver Fibrosis in Chronic Liver Diseases
14:30-14:55		Ching-Sheng Hsu	Chiayi	Sarcopenia in Hepatocellular Carcinoma

14:55-15:20	Chao-Wei Lee	Taoyuan	Skeletal Muscle and Body Fat Mass: Culprit for Poor HCC Outcome	
-------------	--------------	---------	---	--

APASL Symposium 18-HCV: Basic Research: Virology and Immunology				
				Room 201ABC
13:40-15:20				
Moderator	Ming-Lung Yu (Kaohsiung)/Chun-Jen Liu (Taipei)			
Time	No.	Name	City	Topic
13:40-14:05		Chun-Jen Liu	Taipei	Risk, Immune Remodeling and Prevention of HBV Reactivation Following HCV Clearance by DAA in HCV/HBV Dual Infection
14:05-14:30		Robert Thimme	Freiburg	T Cell Responses During HCV Infection and HCC
14:30-14:55		Andrea Cox	Baltimore	Oncogenic Potential After HCV Eradication
14:55-15:20		Chien-Hao Huang	Taoyuan	The Parhogenic Role of Innate CD8+T Cells in Chronic Hepatitis C

APASL Symposium 19-HCC/CC: Surgery and Locoregional Therapy				
				Room 201DEF
13:40-15:20				
Moderator	Shi-Ming Lin (Taoyuan)/Kai-Wen Huang (Taipei)			
Time	No.	Name	City	Topic
13:40-14:05		Chao-Long Chen	Kaohsiung	Evolving Strategies in LDLT for HCC
14:05-14:30		Shuichiro Shiina	Tokyo	Ablation for HCC: RFA, MWA, Cryo, IRE Update
14:30-14:55		Ray Lee		Trans-Arterial Embolization with New Regimens for HCC
14:55-15:20		Hee Chul Park	Seoul	Radiotherapy: Carbon and Proton Beam

State-of-the-Art Lecture 10				
				Plenary Hall
13:40-14:10				
Moderator	Jaw-Ching Wu (Taipei)			
Time	No.	Name	City	Topic
13:40-14:10		Zhigang Tian	Hefei	Breakdown of HBV-Immunotolerance and HCC Development

State-of-the-Art Lecture 11

Plenary Hall

14:15-14:45

Moderator Jean Charles Nault (Paris)

Time	No.	Name	City	Topic
14:15-14:45		Ann-Lii Cheng	Taipei	The Way We Will -- Guideline Harmonization

State-of-the-Art Lecture 12

Plenary Hall

14:50-15:20

Moderator George Lau (Hong Kong)

Time	No.	Name	City	Topic
14:50-15:20		Yen-Hsuan Ni	Taipei	Gut Microbiome Can Modulate the Immune Flare-Up in Chronic Hepatitis B

APASL Symposium 20-Alcohol Related Liver Disease (ALD) and Drug Induced Liver Injury (DILI)

VIP Room

13:40-15:20

Moderator Diana A. Payawal (Manila)/Jee-Fu Huang (Kaohsiung)

Time	No.	Name	City	Topic
13:40-14:05		Dong Joon Kim	Chuncheon	Alcoholic Related Liver Disease in Asia-Pacific
14:05-14:30		Gyongyi szabo	Boston	Gut-Liver Axis in Alcoholic Liver Disease
14:30-14:55		Yi-Shin Huang	Taipei	Update on Dili in Asia-Pacific
14:55-15:20		Shiu-Feng Huang	Miaoli	Pathologic Characteristics of Dili

AARC Session 5: Clinical Case Scenarios of LT in ACLF

South Lounge

14:50-16:20

Time	No.	Name	City	Topic
14:50-15:05	Moderator	Anand Shreshta		Case 1 ACLF in A Morbidly Obese ACLF with HBV Reactivation
14:50-15:05		Ajay Duseja		Case 1 ACLF in A Morbidly Obese ACLF with HBV Reactivation
15:05-15:20	Moderator	Anand Kulkarni		Case 2 ACLF- Alcohol with Recent Alcohol Intake

15:05-15:20		Akash Shukla	Case 2 ACLF- Alcohol with Recent Alcohol Intake
15:20-15:35	Moderator	Ulrich Beuers	Case 3 ACLF - AIH on High Dose Steroids
15:20-15:35		Vinod Arora	Case 3 ACLF - AIH on High Dose Steroids
15:35-15:50	Moderator	Atsushi Tanaka	Case 4 ACLF - ATT Induced DILI in ACLF; How to Transplant
15:35-15:50		Harshad Devarbhavi	Case 4 ACLF - ATT Induced DILI in ACLF; How to Transplant
15:50-16:05	Moderator	S.H. Han	Case 5 ACLF with Sepsis
15:50-16:05			Case 5 ACLF with Sepsis
16:05-16:20	Moderator	Oidov Baatarkhuu	Case 6 ACLF with Circulatory Failure
16:05-16:20		Jun Li	Case 6 ACLF with Circulatory Failure

APASL Symposium 21-Multi-Omics and Liver

Room 102

15:50-17:30				
Moderator	Hung-Chih Yang (Taipei)/Stephanie Ma (Hong Kong)			
Time	No.	Name	City	Topic
15:50-16:15		Adil Mardinoglu	London	Application of Omics Technologies in the Study of Liver Disease
16:15-16:40		Hwai-i Yang	Taipei	Multiomics & Viral Hepatitis
16:40-17:05		Tetsuo Takehara	Osaka	Multiomics Approaches to MAFLD/NASH
17:05-17:30		Bin-Tean Teh	Singapore	Multiomics & Hepatocellular Carcinoma

APASL Symposium 22-HCV: Natural History and Current Therapy (Including Special Populations)

Room 201ABC

15:50-17:30				
Moderator	Mei-Hsuan Lee (Taipei)/Ray Kim (San Francisco)			
Time	No.	Name	City	Topic
15:50-16:15		Fasiha Kanwal	Houston	Long-Term Benefits of Chronic Hepatitis C Patients After Sustained Virological Response
16:15-16:40		Eiichi Ogawa	Fukuoka	Predictors of Advanced Liver Disease of Chronic Hepatitis C Patients After Sustained Virological Response Following DAA Treatment

16:40-17:05	Chen-Hua Liu	Taipei	DAA Treatment in Hepatitis C Special Groups
17:05-17:30	Chia-Yen Dai	Kaohsiung	Unmet Needs in the Management of Chronic Hepatitis C for Elimination
APASL Symposium 23-HCC/CC: Systemic Therapy Including Early Phase Data for Novel Treatments in Cholangiocarcinoma			
Room 201DEF			
15:50-17:05	Moderator Masatoshi Kudo (Osaka)/Chiun Hsu (Taipei)		
Time	No.	Name	City Topic
15:50-16:15		Takuji Okusaka	Tokyo Cytotoxic Chemotherapy for Biliary Tract Cancers
16:15-16:40		Ming-Huang Chen	Taipei Immunotherapy in Biliary Tract Cancer Update
16:40-17:05		Changhoon Yoo	Seoul Translational Research for New Drug Development
Joint Symposium 1: EASL-APASL-Management of Hepatocellular Carcinoma: The East/West Point of Views			
Plenary Hall			
15:50-17:30	Moderator Jean Charles Nault (Paris) /Ann-Lii Cheng (Taipei)		
Time	No.	Name	City Topic
15:50-16:15		Jean Charles Nault	Paris Impact of Etiologies on HCC Biology and Implications for Future Biomarkers Guided Therapies
16:15-16:40		Valerie Chew	Singapore Immune Microenvironment in HBV-Related HCC
16:40-17:05		Maria Reig	Barcelona Systemic Treatments of HCC in Specific Populations (Comorbidities, Transplantation, Bleeding History, Uncontrolled Viral Infection...)
17:05-17:30		Stephen Lam Chan	Hong Kong Systemic Therapy for Viral and Non-Viral HCC: From Asian Point of View
APASL Symposium 24-Special Issues in Asia-Pacific Region			
VIP Room			
15:50-17:55	Moderator Jose Sollano (Manila)/Pin-Nan Cheng (Tainan)		
Time	No.	Name	City Topic
15:50-16:15		Banchob Sripa	Khon Kaen Control of Liver Flukes in Southeast Asia and Impact on Risk of Cholangiocarcinoma

16:15-16:40	Harshad Devarbhavi	Bangalore	Herbal and Dietary Supplement Induced Liver Injury in Asia
16:40-17:05	Oidov Baatarkhuu	Ulan Bator	Mongolia's Experience and Strategies on Combating Common and Uncommon Liver Diseases in Asia
17:05-17:30	Satoshi Kobayashi	Kanazawa	Imaging Diagnosis of Vascular Diseases of the Liver in Asia-Pacific
17:30-17:55	Necati Örmeci	Istanbul	Hydatid Cyst in Asia-Pacific

AARC Session 6: Consensus Statement of LDLT in ACLF

			South Lounge
16:30-17:00			

Time	No.	Name	City	Topic
16:30-17:00		Jin Mo Yang		AARC Session 6: Consensus Statement of LDLT in ACLF

Future Vision of AARC

			South Lounge
17:00-17:20			

Time	No.	Name	City	Topic
17:00-17:20		Shiv Kumar Sarin		Future Vision of AARC

Free Paper 9: EASL-APASL

			North Lounge
15:50-17:30			
Moderator	TBC		

Break/Poster & Exhibition

17:30-18:00			
-------------	--	--	--

Gala Dinner

18:30-21:00			
-------------	--	--	--

Saturday, February 18th

Registration

1F lobby

08:30

Plenary Lecture 3

Plenary Hall

09:00-09:30

Moderator Rong-Nan Chien (Taoyuan)

Time	No.	Name	City	Topic
09:00-09:30		Yun-Fan Liaw	Taoyuan	Management of Finite Nuc Therapy in HBeAg-Negative Patients

Plenary Lecture 4

Plenary Hall

09:30-10:00

Moderator Masao Omata (Tokyo)

Time	No.	Name	City	Topic
09:30-10:00		Shiv Kumar Sarin	New Delhi	ACLF: Recent Advances and Critical Care Management

APASL Symposium 25-Portal Hypertension and Liver Cirrhosis: Basic Research

Room 102

10:20-12:00

Moderator Jordi Gracia-Sancho (Barcelona)/Ying-Ying Yang (Taipei)

Time	No.	Name	City	Topic
10:20-10:45		Jasmohan S. Bajaj	Richmond	Crosstalk Between Intestinal Microbiota and Peripheral/Neuro Inflammation for Hepatic Encephalopathy in Experimental Cirrhosis
10:45-11:10		Yasuko Iwakiri	New Haven	Angiogenic, Lymphatic, and Glymphatic Targets for the Hemodynamic Disarrangements in Experimental Approaches
11:10-11:35		Ying-Ying Yang	Taipei	Advances in the Modulation of the Immunological and Organs (Cardiac and Renal) Dysfunctions in Experimental Cirrhosis
11:35-12:00		Tzung-Yan Lee	Taoyuan	Advances in the Strategies to Attenuates Vasculopathy in Experimental Model of Cirrhotic Portal Hypertension

APASL Symposium 26-HCC/CC: Basic Science and Biomarkers

Room 201ABC

10:20-12:00

Moderator Sheng-Nan Lu (Kaohsiung)/ Osamu Yokosuka(Chiba)

Time	No.	Name	City	Topic
10:20-10:45		Xin Wei Wang	Bethesda	Evolution of Cell Composition During HCC Progression and Treatment

10:45-11:10	Irene Oi-Lin Ng	Hong Kong	The Evolution of Hepatocellular Carcinoma at Single Cell Level
11:10-11:35	Shiou-Hwei Yeh	Taipei	Human Genomic HBV in Hepatocarcinogenesis and Diagnosis
11:35-12:00	Stephanie Ma	Hong Kong	Genetically Defined, Syngeneic Organoid Platform for Understanding Heterogeneity and Response to Therapy in Liver Cancer

APASL Symposium 27-Application of Artificial Intelligence (AI) and Big Data in Hepatology (I)

Room 201DEF

10:20-12:00

Moderator Dar-In Tai (Taoyuan)/Jeong-Hoon Lee (Seoul)

Time	No.	Name	City	Topic
10:20-10:45		Mei-Hsuan Lee	Taipei	Big Data in Liver Diseases: A Look into the Future
10:45-11:10		Terry Cheuk-Fung Yip	Hong Kong	Applying Big Data in Clinical Research on Liver Diseases
11:10-11:35		Jesper Bøje Andersen	Copenhagen	Integrate Multiple–Omics Data Toward Insights into Pathogenesis for Liver Diseases
11:35-12:00		Yasuhito Tanaka	Nagoya	Applying Big Data to Patient Management and Risk Stratification in Clinical Practice

Joint Symposium 2: AASLD-APASL-Can HBV be Cured? Where and How?

Plenary Hall

10:20-12:00

Moderator Ray Kim (San Francisco)/Jia-Horng Kao (Taipei)

Time	No.	Name	City	Topic
10:20-10:40		Haitao Guo	Indianapolis	Current State of HBV Cure: Virological Perspective
10:40-11:00		Antonio Bertoletti	Singapore	Current State of HBV Cure: Immunological Perspective
11:00-11:20		Man Fung Yuen	Hong Kong	Antiviral Compounds for HBV Cure
11:20-11:40		Hung-Chih Yang	Taipei	Looking into the Future: Combination, Duration, Impact on Long Term Outcomes
11:40-12:00	Panel Discussion			

APASL Symposium 28-HBV Reactivation

VIP Room

10:20-12:00

Moderator Teerha Piratvisuth (Songkhla)/Wen-Juei Jeng (Taoyuan)

Time	No.	Name	City	Topic
------	-----	------	------	-------

10:20-10:45		George V. Papatheodoridis	Athens	Off-Nuc Therapy HBV Reactivation
-------------	--	---------------------------	--------	----------------------------------

10:45-11:10		Ming-Lun Yeh	Kaohsiung	HBV Reactivation and Dual HBV+HCV Infection
-------------	--	--------------	-----------	---

11:10-11:35		Shigeru Kusumoto	Nagoya	HBV Reactivation and Immunosuppressive Therapy
-------------	--	------------------	--------	--

11:35-12:00		Yi-Hsiang Huang	Taipei	HBV Reactivation and Immune Checkpoint Inhibitor Therapy
-------------	--	-----------------	--------	--

Free Paper 10: MAFLD (Basic)

North Lounge

15:50-17:30

Moderator Min-Ling Chang / Chun-Yen Lin

Free Paper 11: HBV (Basic)

South Lounge

15:50-17:30

Moderator Jaw-Ching Wu / Chun-Yen Lin

Satellite Symposium 10 Abbvie

Room 102

12:00-13:30

Satellite Symposium 11 Eisai

Room 201ABC

12:00-13:30

Satellite Symposium 12 Roche

Room 201DEF

12:00-13:30

Satellite Symposium 13 Bayer

North Lounge

12:00-13:30

Satellite Symposium 14

South Lounge

12:00-13:30

Satellite Symposium 15 Gilead

VIP Room

12:00-13:30

APASL Symposium 29-Portal Hypertension and Liver Cirrhosis: Natural History, Complications, and Potential Novel Treatments

Room 102

13:40-15:20

Moderator Barjesh Sharma (New Delhi)/Chun-Yen Lin (Taoyuan)

Time	No.	Name	City	Topic
13:40-14:05		Mauro Bernardi	Bologna	Albumin in Decompensated Liver Cirrhosis: Pathogenesis and Implication to Treatment
14:05-14:30		Gin-Ho Lo	Kaohsiung	Non-Selective Beta-Blocker in Liver Cirrhosis: Benefits and Controversials
14:30-14:55		Moon-Young Kim	Wonju	Current Concepts in Coagulation Profile in Cirrhosis and Acute-On-Chronic Liver Failure
14:55-15:20		Ming-Hung Tsai	Taoyuan	Nutrition in Liver Cirrhosis: With a Focus on Critically Ill Cirrhotic Patients

APASL Symposium 30-HCC/CC: Systemic Therapy Including Early Phase Data for Novel Treatments in HCC

Room 201ABC

13:40-15:45

Moderator Sheng-Nan Lu (Kaohsiung)/Yi-Hsiang Huang (Taipei)

Time	No.	Name	City	Topic
13:40-14:05		Stephen Lam Chan	Hong Kong	Change Landscape of Systemic Therapy for Unresectable HCC
14:05-14:30		Valerie Chew	Singapore	Understanding Immunobiology of Hepatocellular Carcinoma for Biomarkers and Therapeutic Discovery
14:30-14:55		Tim Greten	Bethesda	Immune-Related Biomarkers for Systemic Therapy of HCC
14:55-15:20		Bruno Sangro	Pamplona	Systemic Therapy for HCC: From Guidelines to the Real World (Western Perspective)
15:20-15:45		Yi-Hsiang Huang	Taipei	Systemic Therapy for HCC: From Guidelines to the Real World (Asian Perspective)

APASL Symposium 31-Application of Artificial Intelligence (AI) and Big Data in Hepatology (II)

Room 201DEF

13:40-15:45

Moderator Yasuhito Tanaka (Nagoya)/Mei-Hsuan Lee (Taipei)

Time	No.	Name	City	Topic
13:40-14:05		Mazen Nouredin	Los Angeles	Application of Artificial Intelligence for the Diagnosis and Treatment of Liver Diseases
14:05-14:30		Jeong-Hoon Lee	Seoul	Artificial Intelligence-Based Prediction Model for CHB Patients
14:30-14:55		Ashok Choudhury	New Delhi	Liver Failure and Liver Transplant: Implication of AI Based Model
14:55-15:20		Dar-In Tai	Taoyuan	Accurate and Generalizable Quantitative Scoring of Liver Steatosis from Ultrasound Images Via Scalable Deep Learning
15:20-15:45		Tung-Hung Su	Taipei	Artificial Intelligence in Precision Medicine in Hepatology

State-of-the-Art Lecture 13

Plenary Hall

13:40-14:10

Moderator Dong Jin Suh (Seoul)

Time	No.	Name	City	Topic
13:40-14:10		Jia-Horng Kao	Taipei	Precision Medicine in the Management of Chronic Hepatitis B

State-of-the-Art Lecture 14

Plenary Hall

14:15-14:45

Moderator Jin Mo Yang (Seoul)

Time	No.	Name	City	Topic
14:15-14:45		Won-Il Jeong	Daejeon	Metabolic, Immunologic and Neurologic Signals in Alcohol-Related Liver Disease

State-of-the-Art Lecture 15

Plenary Hall

14:50-15:20

Moderator A. Kadir Dokmeci (Ankara)

Time	No.	Name	City	Topic
14:50-15:20		Jidong Jia	Beijing	Primary Biliary Cholangitis

Free Paper 12: MAFLD (Clinical)

North Lounge

15:50-17:30

Moderator Wan-Long Chuang / Saeed Hamid

Free Paper 13: HBV (Clinical)

South Lounge

15:50-17:30

Moderator Tsung-Hui Hu / I-Cheng Lee

Breaker/Poster & Exhibition

Room102/Plenary Hall/South Lounge/North Lounge/VIP Room

15:20-15:50

APASL Symposium 32-COVID-19 and the Liver

VIP Room

13:40-15:20

Moderator Chung-Feng Huang (Kaohsiung)/Hwai-i Yang (Taipei)

Time	No.	Name	City	Topic
13:40-14:05		Oren K. Fix	Washington	COVID-19 Vaccination in Patients with Liver Diseases
14:05-14:30		Shiv Kumar Sarin	New Delhi	Pre-Existing Liver Disease is Associated with Poor Outcome in Patients With SARS-CoV2 Infection
14:30-14:55		Grace Lai-Hung Wong	Hong Kong	Management of Patients with Liver Derangement During the COVID-19 Pandemic
14:55-15:20		Gamal Shiha		The Impact of COVID-19 pandemic on the Elimination Program of Viral Hepatitis in Egypt

APASL Symposium 33-HCV: Extrahepatic Manifestation of HCV

Room 102

15:50-17:30

Moderator Chen-Hua Liu (Taipei)/Chia-Yen Dai (Kaohsiung)

Time	No.	Name	City	Topic
15:50-16:15		Darrell Crawford	Brisbane	Non-Hepatic Malignancies
16:15-16:40		Pin-Nan Cheng	Tainan	Mixed Cryoglobulinemia and Rheumatic Diseases
16:40-17:05		Diana A. Payawal	Manila	Metabolic Complications and CKD

17:05-17:30		Tawesak Tanwandee	Bangkok	Impact of Direct-Acting Antiviral Therapy
-------------	--	-------------------	---------	---

Grand Round-Acute-on-chronic Liver Failure				
				Plenary Hall
15:50-17:30				
Moderator	Shiv Kumar Sarin (New Delhi)/Jasmohan S. Bajaj (Richmond)			
Time	No.	Name	City	Topic
15:50-17:30		Ashok Choudhury	New Delhi	Asian Perspective
15:50-17:30		Richard Moreau	Paris	Western Perspective

APASL Symposium 34-Liver Transplantation				
				VIP Room
15:50-17:30				
Moderator	Chao-Long Chen (Kaohsiung)/Neil Mehta (Cleveland)			
Time	No.	Name	City	Topic
15:50-16:15		Kwan Man	Hong Kong	Liver Transplantation Using Steatotic Liver Graft
16:15-16:40		Wei-Chen Lee	Taoyuan	Management (Immunotherapy) of HCC Before and After Liver Transplantation
16:40-17:05		Sanjiv Saigal	Gurgaon	Liver Transplantation Beyond Conventional Criteria
17:05-17:30		Mamatha Bhat	Toronto	Precision Medicine to Improve Long-Term Outcomes After Liver Transplantation

Free Paper 14: MAFLD (Clinical)				
				North Lounge
15:50-17:30				
Moderator	Ching-Sheng Hsu / Ming-Lun Yeh			

Free Paper 15: Miscellaneous				
				South Lounge
15:50-17:30				
Moderator	Huey-Ling Chen / Saeed Hamid			

Satellite Symposium 16: Gilead				
				Room 201 ABC
17:40-19:00				

Satellite Symposium 17: Eisai

Room 201 DEF

17:40-19:00

Satellite Symposium 18: AstraZeneca

North Lounge

17:40-19:00

Satellite Symposium 19: BMS

South Lounge

17:40-19:00

Satellite Symposium 20

VIP Room

17:40-19:00

Sunday, February 19th

Registration

1F lobby

08:30

YIA Award

Room 201ABC

09:00-10:30

Moderator TBC

Time	No.	Name	City	Topic
------	-----	------	------	-------

Coalition to Eradicate Virtual Hepatitis in Asia Pacific (CEVHAP) Symposium

Room 201DEF

09:00-10:30

Moderator TBC

Time	No.	Name	City	Topic
------	-----	------	------	-------

APASL 2023 Scientific Debrief: Hepatitis, Cirrhosis, Liver Cancer, NASH

Room 201ABC

10:50-12:30

Moderator Jia-Horng Kao (Taipei)/Wan-Long Chuang (Kaohsiung)

Time	No.	Name	City	Topic
------	-----	------	------	-------

10:50-11:15		Hung-Chih Yang	Taipei	Scientific Debrief: Viral hepatitis
-------------	--	----------------	--------	-------------------------------------

11:15-11:40		Ying-Ying Yang	Taipei	Scientific Debrief: Cirrhosis
-------------	--	----------------	--------	-------------------------------

11:40-12:05		Chiun Hsu	Taipei	Scientific Debrief: HCC
-------------	--	-----------	--------	-------------------------

12:05-12:30		Jee-Fu Huang	Kaohsiung	Scientific Debrief: NASH
-------------	--	--------------	-----------	--------------------------

Coalition to Eradicate Virtual Hepatitis in Asia Pacific (CEVHAP) Symposium

Room 201DEF

09:00-10:30

Moderator TBC

Time	No.	Name	City	Topic
------	-----	------	------	-------

Closing Ceremony

Room 201

12:30-13:00